Cartesian Therapeutics, Inc. (RNAC): Cash & Equivalents
$125.14M
As of 2025-12-31
$147.61M
As of 2026-06-30
+5.5%
3-year compound annual growth
-2.0%
5-year compound annual growth
+14.5%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $125.14M | -41.1% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $212.61M | +176.4% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $76.91M | -27.7% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $106.44M | -6.7% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $114.06M | -17.8% | 2024-03-07, Balance as of period end |
| 2020-12-31 | $138.69M | +54.3% | 2023-03-02, Balance as of period end |
| 2019-12-31 | $89.89M | +140.3% | 2022-03-10, Balance as of period end |
| 2018-12-31 | $37.40M | -47.0% | 2021-03-12, Balance as of period end |
| 2017-12-31 | $70.62M | +20.4% | 2020-03-12, Balance as of period end |
| 2016-12-31 | $58.66M | +81.4% | 2019-03-15, Balance as of period end |
| 2015-12-31 | $32.34M | +94.9% | 2018-03-15, Balance as of period end |
| 2014-12-31 | $16.59M | n/a | 2017-03-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $125.14M | -41.1% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $101.58M | -68.8% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $3.09M | -44.0% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $109.52M | +71.0% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $16.07M | -16.3% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $3.24M | +0.2% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $51.09M | +124.1% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $5.21M | -16.1% |
Compare RNAC, UPB, TXMD, GOVX side by side · Screen every company in Pharmaceutical Preparations ↗